Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Sirius Huang -- 2953 2022-10-26 01:37:21

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. HIV Vaccine Development. Encyclopedia. Available online: https://encyclopedia.pub/entry/31506 (accessed on 17 October 2026).
HandWiki. HIV Vaccine Development. Encyclopedia. Available at: https://encyclopedia.pub/entry/31506. Accessed October 17, 2026.
HandWiki. "HIV Vaccine Development" Encyclopedia, https://encyclopedia.pub/entry/31506 (accessed October 17, 2026).
HandWiki. (2022, October 27). HIV Vaccine Development. In Encyclopedia. https://encyclopedia.pub/entry/31506
HandWiki. "HIV Vaccine Development." Encyclopedia. Web. 27 October, 2022.
HIV Vaccine Development
Edit
The content is sourced from: https://handwiki.org/wiki/Unsolved:HIV_vaccine

An HIV vaccine can be either a preventive vaccine or a therapeutic vaccine, which means it can either protect individuals from being infected with HIV or treat HIV-infected individuals. And it can either induce an immune response against HIV (active vaccination approach) or consist of preformed antibodies against HIV (passive vaccination approach). There is currently no licensed HIV vaccine on the market, but multiple research projects are trying to find an effective vaccine. Evidence observed from humans shows that a vaccine may be possible: Some, but certainly not all, HIV-infected individuals naturally produce broadly neutralizing antibodies which keep the virus suppressed, and these people remain asymptomatic for decades. Potential broadly neutralizing antibodies have been cloned in the laboratory (monoclonal antibodies) and are being tested in passive vaccination clinical trials. Many trials have shown no efficacy, but one HIV vaccine regimen, RV 144, has been shown to prevent HIV in some individuals in Thailand. The urgency of the search for a vaccine against HIV stems from the AIDS-related death toll of over 35 million people since 1981. In 2002, AIDS became the primary cause of death due to an infectious agent in Africa. Alternative medical treatments to a vaccine exist. For the treatment of HIV-infected individuals, highly active antiretroviral therapy (HAART) medication has been demonstrated to provide many benefits to HIV-infected individuals, including improved health, increased lifespan, control of viremia, and prevention of transmission to babies and partners. HAART must be taken lifelong without interruption to be effective, and cannot cure HIV. Options for the prevention of HIV infection in HIV-uninfected individuals include safer sex (for example condom use), antiretroviral strategies (pre-exposure prophylaxis and post-exposure prophylaxis) and medical male circumcision. Vaccination has proved a powerful public health tool in vanquishing other diseases, and an HIV vaccine is generally considered as the most likely, and perhaps the only way by which the HIV pandemic can be halted. However, HIV remains a challenging target for a vaccine.

antiretroviral therapy public health antiretroviral

References

  1. Shilts, Randy (1987). And the Band Played On: Politics, People, and the AIDS Epidemic (2007 ed.). St. Martin's Press. p. 451. ISBN 978-0-312-24135-3. https://archive.org/details/andbandplayedonp00shil_0/page/451. 
  2. "An HIV vaccine: breaking the paradigms". Proc. Am. Assoc. Phys. 108 (1): 6–13. 1996. PMID 8834058.  http://www.ncbi.nlm.nih.gov/pubmed/8834058
  3. "HIV vaccine efficacy trials: towards the future of HIV prevention". Infectious Disease Clinics of North America 21 (1): 201–17, x. March 2007. doi:10.1016/j.idc.2007.01.006. PMID 17502236.  https://dx.doi.org/10.1016%2Fj.idc.2007.01.006
  4. "The hope for an HIV vaccine based on induction of CD8+ T lymphocytes--a review". Memórias do Instituto Oswaldo Cruz 103 (2): 119–29. March 2008. doi:10.1590/S0074-02762008000200001. PMID 18425263.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2997999
  5. Nixon, Douglas, ed (October 2007). "Design and pre-clinical evaluation of a universal HIV-1 vaccine". PLOS ONE 2 (10): e984. doi:10.1371/journal.pone.0000984. PMID 17912361. Bibcode: 2007PLoSO...2..984L.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1991584
  6. "Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo". Immunity 10 (4): 431–8. April 1999. doi:10.1016/S1074-7613(00)80043-6. PMID 10229186.  https://dx.doi.org/10.1016%2FS1074-7613%2800%2980043-6
  7. "Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160". Nature 345 (6276): 622–5. June 1990. doi:10.1038/345622a0. PMID 2190095. Bibcode: 1990Natur.345..622B.  https://dx.doi.org/10.1038%2F345622a0
  8. "Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines". Journal of Virology 72 (2): 1552–76. February 1998. doi:10.1128/JVI.72.2.1552-1576.1998. PMID 9445059.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=124637
  9. "The use of nonhuman primate models in HIV vaccine development". PLOS Medicine 5 (8): e173. August 2008. doi:10.1371/journal.pmed.0050173. PMID 18700814.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2504486
  10. "Generalized immune activation as a direct result of activated CD4+ T cell killing". Journal of Biology 8 (10): 93. 2009. doi:10.1186/jbiol194. PMID 19943952.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2790834
  11. "Life and death as a T lymphocyte: from immune protection to HIV pathogenesis". Journal of Biology 8 (10): 91. 2009. doi:10.1186/jbiol198. PMID 19951397.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2790836
  12. "Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial". The Lancet. HIV 5 (7): e366–e378. June 2018. doi:10.1016/S2352-3018(18)30071-7. PMID 29898870.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6028742
  13. "Recent progress in HIV vaccines inducing mucosal immune responses". AIDS 28 (12): 1701–18. July 2014. doi:10.1097/qad.0000000000000308. PMID 25009956.  https://dx.doi.org/10.1097%2Fqad.0000000000000308
  14. "New Vaccine Could Turn HIV Into Minor Infection". Fox News. 2011-09-29. http://www.foxnews.com/health/2011/09/29/new-vaccine-could-turn-hiv-into-minor-infection/. 
  15. "First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses". Retrovirology 13 (1): 82. November 2016. doi:10.1186/s12977-016-0317-2. PMID 27894306.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5126836
  16. "New HIV Vaccine Proves Successful In Phase 1 Human Trial". Medical Daily (New York). 2013-09-04. http://www.medicaldaily.com/new-hiv-vaccine-proves-successful-phase-1-human-trial-255439/. 
  17. "STEP Study Locations". http://www.stepstudies.com/new/locations.shtml. 
  18. Joint United Nations Programme on HIV/AIDS (UNAIDS) (December 2005). "AIDS epidemic update". World Health Organization. http://www.who.int/hiv/epi-update2005_en.pdf. 
  19. Efficacy Results from the STEP Study (Merck V520 Protocol 023/HVTN 502): A Phase II Test-of-Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine http://www.hvtn.org/science/step_buch.html
  20. "The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?". The Journal of Experimental Medicine 205 (1): 7–12. January 2008. doi:10.1084/jem.20072681. PMID 18195078.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2234358
  21. "The aftermath of the Merck's HIV vaccine trial". Retrovirology 5: 56. July 2008. doi:10.1186/1742-4690-5-56. PMID 18597681.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2483718
  22. "Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials". Human Vaccines & Immunotherapeutics 14 (9): 2116–2127. April 2018. doi:10.1080/21645515.2018.1462640. PMID 29683765.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6183277
  23. "Candidate for new AIDS vaccine advances to next phase of pre-approval trials- Technology News, Firstpost" (in en-US). 2018-07-08. https://www.firstpost.com/tech/science/candidate-for-new-aids-vaccine-advances-to-next-phase-of-pre-approval-trials-4690471.html. 
  24. "Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial". Retrovirology 13: 21. April 2016. doi:10.1186/s12977-016-0251-3. PMID 27036656.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4818470
  25. "Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand". The New England Journal of Medicine 361 (23): 2209–20. December 2009. doi:10.1056/NEJMoa0908492. PMID 19843557.  https://dx.doi.org/10.1056%2FNEJMoa0908492
  26. Callaway, Ewen (16 September 2011). "Clues emerge to explain first successful HIV vaccine trial". Nature. doi:10.1038/news.2011.541.  https://dx.doi.org/10.1038%2Fnews.2011.541
  27. "Experimental HIV vaccine regimen ineffective in preventing HIV". NIH. 3 February 2020. https://www.nih.gov/news-events/news-releases/experimental-hiv-vaccine-regimen-ineffective-preventing-hiv. Retrieved 4 February 2020. 
  28. 15 July 2019 (2019-07-15). "NIH and partners to launch HIV vaccine efficacy trial in the Americas and Europe". National Institutes of Health. https://www.nih.gov/news-events/news-releases/nih-partners-launch-hiv-vaccine-efficacy-trial-americas-europe. 
  29. "Investing to End the AIDS Epidemic: A new Era for HIV Prevention Research and Development". http://www.hivresourcetracking.org/sites/default/files/July%202012%20Investing%20to%20End%20the%20AIDS%20Epidemic-%20A%20New%20Era%20for%20HIV%20Prevention%20Research%20&%20Development.pdf. 
  30. Advanced Purchase Commitments for a Malaria Vaccine: Estimating Costs and Effectiveness. April 2005. doi:10.2139/ssrn.696741.  https://dx.doi.org/10.2139%2Fssrn.696741
  31. Collier, Leslie; Balows, Albert; Sussman, Max (1998). Mahy, Brian; Collier, Leslie. eds. Virology. Topley and Wilson's Microbiology and Microbial Infections. 1 (ninth ed.). Hodder Education Publishers. pp. 75–91. ISBN 978-0-340-66316-5. 
  32. "A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening". Journal of Medicinal Chemistry 45 (8): 1712–22. April 2002. doi:10.1021/jm010533y. PMID 11931626.  https://dx.doi.org/10.1021%2Fjm010533y
  33. Compared with overview in: Fisher, Bruce; Harvey, Richard P.; Champe, Pamela C. (2007). Lippincott's Illustrated Reviews: Microbiology (Lippincott's Illustrated Reviews Series). Hagerstown, MD: Lippincott Williams & Wilkins. ISBN:0-7817-8215-5. Page 3
  34. HIV Sequence Compendium (Report). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM, LA-UR 17-25240. 2017. 
  35. "Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides". Proceedings of the National Academy of Sciences of the United States of America 95 (16): 9134–9. August 1998. doi:10.1073/pnas.95.16.9134. PMID 9689046. Bibcode: 1998PNAS...95.9134M.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=21304
  36. "Potential utility of GB virus type C as a preventive vaccine for HIV-1". Expert Review of Vaccines 11 (3): 335–47. March 2012. doi:10.1586/erv.11.191. PMID 22380825.  https://dx.doi.org/10.1586%2Ferv.11.191
  37. "Construction of a live-attenuated HIV-1 vaccine through genetic code expansion". Angewandte Chemie 53 (19): 4867–71. May 2014. doi:10.1002/anie.201402092. PMID 24715496.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4984542
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Immunology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 762
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 27 Oct 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback